Latest News

Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares

Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi,...

read more

Latest News

Weekly News Roundup | 16 November 2026

Weekly News Roundup | 16 November 2026

Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Rethinking Biologics Plants to Earn Attractive Returns

Rethinking Biologics Plants to Earn Attractive Returns

The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

read more
ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

read more
Rethinking Biologics Plants to Earn Attractive Returns

Rethinking Biologics Plants to Earn Attractive Returns

The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

read more
ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 2 November 2026

Weekly News Roundup | 2 November 2026

Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

read more
What Are You Signing When the AI Wrote the Note?

What Are You Signing When the AI Wrote the Note?

Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...

read more
Clinical Trial Results 30 October 2026

Clinical Trial Results 30 October 2026

Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...

read more
Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....

read more
Interoperability Begins Where Data Exchange Ends

Interoperability Begins Where Data Exchange Ends

Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

read more

Further News

The Signature Is the Safeguard: Where AI Belongs in Mental Health Care

Most of the argument about AI in mental health care is about chatbots that talk like therapists. The bigger change is happening somewhere less visible: in the notes, forms and insurance paperwork that sit between a clinician and the next person they are trying to...

Why Medical Electronics Are the Hardest E-Waste to Recycle

Single-use medical electronics are one of the fastest-growing sources of electronic waste, yet almost none of their metals or batteries are recovered. The barrier is not technology. It is contamination, and the cost that comes with it. Every week or two, millions of...

Weekly News Roundup | 9 November 2026

Life science news 9 November 2026: two US regulatory decisions, three UK updates, two licensing deals and one acquisition. The FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer. AbbVie licensed an oral IBD candidate from Nxera in a deal...

Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

What Happened When We Gave Business Classes Our Real Production Data

At Karviva, we used several Google Sheets to keep track of ingredients, materials, production and orders. As the business grew, keeping those records connected became harder. We needed to plan production more reliably and trace each batch from its ingredients through...

Clinical Trial Results 6 November 2026

The clinical trial results 6 November 2026 span immune thrombocytopenia, anaemia in chronic kidney disease, red cell transfusion and pterygium. InnoCare’s orelabrutinib met its primary endpoint in chronic primary immune thrombocytopenia. Akebia’s three-times-weekly...

AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development

Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...

MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?

MariTide approval depends on Phase 3 data due in 2027. See what Amgen has disclosed, how the FDA review clock works and what comes next.

    In Vivo CAR-T Is Shifting the Engineering Challenge Into Delivery

    CAR T-cell therapy is revolutionizing cancer treatment and being applied to a variety of other indications, but the approach relies on engineering a patient’s immune cells to recognize and attack cancer. Producing those cells can involve a complex, resource- and...

    AbbVie Nxera Deal: What Does AbbVie Get for $100 Million Upfront?

    The AbbVie Nxera deal gives AbbVie global IBD rights to oral EP4 agonist NXE0033744 for $100 million upfront. Antitrust clearance is pending.

      Hygiene Poverty and the Overlooked Toileting Needs of Women

      If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

      Pharma Q3 2026 Earnings: GLP-1s, the Keytruda Cliff and Vaccines

      Eli Lilly began 2026 expecting revenue of $80bn to $83bn. After its third quarter, it now expects $91bn to $92bn. Lilly’s sales reached $24.4bn in the three months to September, up 39%. Most of its large peers grew in single digits. Read together, pharma Q3 2026...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.